Compare Definium Therapeutics Inc. Common Shares (DFTX) vs Jabil Inc (JBL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Definium Therapeutics Inc. Common Shares vs Jabil Inc — how do they compare? Definium Therapeutics Inc. Common Shares trades at $34.01 (market cap $4.71B), while Jabil Inc trades at $302.32 (market cap $31.38B). The key difference: Jabil Inc is far larger — about 6.7× Definium Therapeutics Inc. Common Shares's market cap, and Jabil Inc pays a 0.11% dividend while Definium Therapeutics Inc. Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and Jabil Inc for 23 Days on average.
| DFTX | JBL | |
|---|---|---|
Market Cap | $4.71B | $31.38B |
Volume | 1,966,636 | 1,418,629 |
Sector | Health | Technology |
52-Week High | $48.45 | $385.50 |
52-Week Low | $10.68 | $192.49 |
Typical Hold Time | 0 Days | 23 Days |
Enterprise Value | $3.67B | $33.66B |
Dividend Yield | — | 0.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
JBL trades at $299.47, down 3.14% today amid a bearish technical signal, though recent Q4 2026 earnings beat expectations with EPS of $4.40 versus $4.07 expected. The company shows strong fundamentals with revenue growth to $29.80B in 2025 and projected 24% growth in fiscal 2027 driven by AI infrastructure demand. Analyst consensus remains bullish with a $434.75 price target, representing 45% upside potential from current levels.
The stock presents a compelling growth opportunity with robust AI-driven expansion and strong institutional support, though technical weakness and market volatility pose near-term risks. With zero sell ratings and 61% buy recommendations, Wall Street sees significant upside despite recent price pressure from broader market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Definium Therapeutics Inc. Common Shares
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →About Jabil Inc
Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.
Read more on JBL →
